HCT-116人結(jié)腸癌細(xì)胞（附
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/12 8:56:31
- 訪問(wèn)次數(shù) 136
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
人結(jié)腸癌細(xì)胞HCT-116
diklerent tumor microenvironments (TME). This means that the eklicacy of immunotherapy in actual applications will, therefore, have diklerent results. Existing tumor immune subtype studies have mostly focused on immune cells, stromal cells, genes and molecules without considering the presence of microbes. Some studies have shown that
accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.As the first compartment of the protein secretory pathway, the endoplasmic reticulum (ER) acts as a protein synthesis factory, maintaining proteostasis and ER homeostasis. However, a variety of intrinsic and extrinsic perturbations, such as cancer, can disrupt the
| 種屬 | 人 |
| 別稱 | HCT-116; HCT.116; HCT_116; HCT116; CoCL2 |
| 組織來(lái)源 | 結(jié)腸 |
| 疾病 | 結(jié)直腸癌 |
| 傳代比例/細(xì)胞消化 | 1：2-1:3傳代 ，消化1-2分鐘 ， |
| 培養(yǎng)基配置 | McCoy’s 5A 培養(yǎng)基；10%胎牛血清；1%雙抗 |
| 簡(jiǎn)介 | HCT116是1979年M.Brattain等從患結(jié)腸癌的男性病人中分離的三株惡性細(xì)胞之一。在半固體瓊脂糖培養(yǎng)基中形成克 隆。HCT116在無(wú)胸腺的裸鼠有致瘤性 ，形成上皮樣的腫瘤 |
| 形態(tài) | 上皮細(xì)胞樣 |
| 生長(zhǎng)特征 | 貼壁生長(zhǎng) |
| 倍增時(shí)間 | ~48h |
| 基因表達(dá) | carcinoembryonic antigen (CEA) 1 ng per 1×10^6 cells per 10 days |
| 致瘤性 | Yes, in nude mice |
| STR | Amelogenin：X ，Y；CSF1PO：7 ，10；D13S317：10 ，12；D16S539：11 ，13；D18S51：16 ，17； D19S433：12 ，13；D21S11：29 ，30；D2S1338：16；D3S1358：12 ，18 ，19；D5S818：10 ，11； D7S820：11 ，12；D8S1179：12 ，14；FGA：18 ，23；TH01：8 ，9；TPOX：8；vWA：17 ，22； |
| 保藏機(jī)構(gòu) | ATCC; CCL-247 |
diklerent tumor microenvironments (TME). This means that the eklicacy of immunotherapy in actual applications will, therefore, have diklerent results. Existing tumor immune subtype studies have mostly focused on immune cells, stromal cells, genes and molecules without considering the presence of microbes. Some studies have shown that
accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.As the first compartment of the protein secretory pathway, the endoplasmic reticulum (ER) acts as a protein synthesis factory, maintaining proteostasis and ER homeostasis. However, a variety of intrinsic and extrinsic perturbations, such as cancer, can disrupt the
采購(gòu)中心
化工儀器網(wǎng)